Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
115.70
-1.97 (-1.67%)
Sep 29, 2026, 2:31 PM EDT - Market open
Insmed Revenue
Insmed had revenue of $425.49M in the quarter ending June 30, 2026, with 296.11% growth. This brings the company's revenue in the last twelve months to $1.14B, up 185.76% year-over-year. In the year 2025, Insmed had annual revenue of $606.42M with 66.73% growth.
Revenue (ttm)
$1.14B
Revenue Growth
+185.76%
P/S Ratio
22.24
Revenue / Employee
$683,675
Employees
1,664
Market Cap
25.27B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 606.42M | 242.72M | 66.73% |
| Dec 31, 2024 | 363.71M | 58.50M | 19.17% |
| Dec 31, 2023 | 305.21M | 59.85M | 24.39% |
| Dec 31, 2022 | 245.36M | 56.90M | 30.19% |
| Dec 31, 2021 | 188.46M | 24.05M | 14.63% |
| Dec 31, 2020 | 164.41M | 27.95M | 20.48% |
| Dec 31, 2019 | 136.47M | 126.63M | 1,287.56% |
| Dec 31, 2018 | 9.84M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 11.50M | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 4.42M | -2.50M | -36.18% |
| Dec 31, 2010 | 6.92M | -3.45M | -33.28% |
| Dec 31, 2009 | 10.37M | -1.33M | -11.33% |
| Dec 31, 2008 | 11.70M | 4.12M | 54.32% |
| Dec 31, 2007 | 7.58M | 6.56M | 639.61% |
| Dec 31, 2006 | 1.03M | 894.00K | 682.44% |
| Dec 31, 2005 | 131.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 6.13B |
| Incyte | 5.82B |
| Alnylam Pharmaceuticals | 4.80B |
| Jazz Pharmaceuticals | 4.60B |
| Genmab | 4.13B |
| BioNTech SE | 3.03B |
| Royalty Pharma | 2.54B |
| Exelixis | 2.44B |
INSM News
- 5 days ago - Insmed resumed with a Buy at Goldman Sachs - TheFly
- 8 days ago - Insmed says FDA grants Priority Review to sNDA for Arikayce - TheFly
- 8 days ago - FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 - PRNewsWire
- 13 days ago - Insmed Expands Community Impact During Fifth Annual Global Day of Good - PRNewsWire
- 14 days ago - Insmed price target lowered to $198 from $212 at Roth Capital - TheFly
- 15 days ago - Insmed Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 20 days ago - Insmed Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 25 days ago - Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire